MAIA Biotechnology, Inc. (MAIA)
NYSEAMERICAN: MAIA · Real-Time Price · USD
1.770
+0.030 (1.72%)
Jun 27, 2025, 4:00 PM - Market closed
Company Description
MAIA Biotechnology, Inc., together with its subsidiaries, immuno-oncology company, focuses on the development and commercialization of drugs with novel mechanisms of action that are intended to improve and extend the lives of people with cancer.
Its lead program is THIO, a potential cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells.
The company was incorporated in 2018 and is headquartered in Chicago, Illinois.
MAIA Biotechnology, Inc.
| Country | United States |
| Founded | 2018 |
| IPO Date | Jul 28, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 13 |
| CEO | Vlad Vitoc |
Contact Details
Address: 444 West Lake Street, Suite 1700 Chicago, Illinois 60606 United States | |
| Phone | 312-416-8592 |
| Website | maiabiotech.com |
Stock Details
| Ticker Symbol | MAIA |
| Exchange | NYSEAMERICAN |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $5.00 |
| CIK Code | 0001878313 |
| CUSIP Number | 552641102 |
| ISIN Number | US5526411021 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Vlad Vitoc M.B.A., M.D. | Co-Founder, President, Chief Executive Officer and Chairman of the Board of Directors |
| Jeffrey C. Himmelreich | Head of Finance and Principal Financial and Accounting Officer |
| Dr. Sergei M. Gryaznov Ph.D. | Chief Scientific Officer |
| Linda Moreira | Company Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 26, 2025 | 8-K | Current Report |
| Jun 24, 2025 | 8-K | Current Report |
| Jun 18, 2025 | 8-K | Current Report |
| Jun 17, 2025 | 8-K | Current Report |
| Jun 11, 2025 | D | Notice of Exempt Offering of Securities |
| Jun 5, 2025 | 8-K | Current Report |
| Jun 2, 2025 | 8-K | Current Report |
| May 28, 2025 | 8-K | Current Report |
| May 23, 2025 | 8-K | Current Report |
| May 22, 2025 | 8-K | Current Report |